A61K 35/16, A61K 2035/122, A61K 35/44, A61K 31/00, A61K 38/17, A61K 48/00, C07H 21/04, C07K 14/435, C07K 14/47, C07K 14/575, C12N 5/06, C12N 9/00, C12N 9/64, C12P 21/02, C12Q 1/68
Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, AÎ² phagocytic activity was increased and soluble and insoluble AÎ² protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of AÎ²1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.
Tan, Jun and Sanberg, Paul R., "HUCBC treatment of amyloid-associated disease" (2018). USF Patents. 1058.
University of South Florida